Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  gemcitabine hydrochloride
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 895 for your search:
Start Over
A Study of Second-Line Therapy With Tarceva (Erlotinib) in Patients With Non-Small Cell Lung Cancer
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ML29028, NCT02000531
Combination Chemotherapy in Treating Patients With Transitional Cell Cancer of the Urothelium
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: EORTC-30986, EORTC-GU-30986, NCT00014274
Gemcitabine and Radiation Therapy Compared With Gemcitabine Alone in Treating Patients Who Have Undergone Surgery for Pancreatic Cancer
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: EORTC-40013-22012, EORTC-40013, EORTC-22012, FFCD-0304, EU-20540, NCT00064207
Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 to 75
Sponsor: Other
Protocol IDs: CDR0000430100, FRE-FNCLCC-ACCORD-11/0402, EU-20512, NCT00112658
Fluorouracil, Cisplatin, and Radiation Therapy or Gemcitabine and Oxaliplatin in Treating Patients With Nonmetastatic Biliary Tract Cancer That Cannot Be Removed By Surgery
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000470411, FFCD-9902, SANOFI-FFCD-9902, LILLY-FFCD-9902, FFCD-FNCLCC-SFRO-9902, NCT00304135
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA183-002, NCT00389155
Immunotherapy With TG4010 in Patients With Advanced Non-Small Cell Lung Cancer
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: TG4010.09, NCT00415818
Nimotuzumab in Adults With Pancreatic Cancer
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: OSAG101-PCS07, NCT00561990
Chemotherapy With or Without Enoxaparin in Pancreatic Cancer
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: CONKO 004, CCT-NAPN-16752, NCT00785421
Gemcitabine or Combination Chemotherapy Followed by Chemoradiation for Stage IB, II, or III Pancreatic Cancer
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 to 75
Sponsor: Other
Protocol IDs: CDR0000641309, PACT-7, SRSI-PACT-7, EU-20932, NCT00960284
Cediranib Versus Placebo Plus Cisplatin/Gemcitabine Chemotherapy for Patients With Advanced Biliary Tract Cancers
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: ABC-03 09/0193, NCT00939848
Cisplatin and RT With or Without Gemcitabine, Carboplatin, and Paclitaxel in Treating Patients With Locally Advanced NPC
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000657121, SINGAPORE-NCC0901, NCC0901, NCT00997906
Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CC-5013-DLC-001, NCT01197560
Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 12154, NCT01438112
Phase III Randomized Study of Marimastat (a Matrix Metalloproteinase Inhibitor) vs Gemcitabine as First-Line Therapy for Pancreatic Cancer (Summary Last Modified 03/2002)
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: BB-C03/IVB/128, NCI-V96-0908
Phase III Randomized Study of Weekly Intravenous P-30 Protein plus Daily Oral Tamoxifen vs Weekly Intravenous Gemcitabine for Advanced Pancreatic Cancer (Summary Last Modified 08/98)
Phase: Phase III
Type: Treatment
Status: Closed
Age: 21 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ALFACELL-P30-303, NCI-V96-0938
Fluorouracil, Gemcitabine, and Radiation Therapy in Treating Patients With Cancer of the Pancreas
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: RTOG-9704, CDR0000066076, E-R9704, SWOG-R9704, NCT00003216
Phase III Randomized Study of BAY 12-9566 Versus Gemcitabine in Patients With Advanced or Metastatic Adenocarcinoma of the Pancreas
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CAN-NCIC-PA1, BAYER-STR-CO2, PA1
Combination Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 to 75
Sponsor: Other
Protocol IDs: EORTC-08975, NCT00003589
Start Over